About: Considerations in treating patients with advance lung cancer during the epidemic outbreak of novel coronavirus (SARS-CoV-2)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Considerations in treating patients with advance lung cancer during the epidemic outbreak of novel coronavirus (SARS-CoV-2) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Considerations in treating patients with advance lung cancer during the epidemic outbreak of novel coronavirus (SARS-CoV-2)
Creator	Wang, Yizhuo Wang, · Guo, Ye Xu, Dongsheng Xu, Yinghui Cai, Yangyang Chao Sun, · Ma, · Shi Qiu, ·
Source	Medline; PMC
abstract	The outbreak of pneumonia caused by novel coronavirus (SARS-CoV-2) in Wuhan, China, at the end of 2019 quickly escalated into a global health emergency. Since its outbreak until the 29th of April 2020, the pandemic has affected more than 3 million of people and caused 207,973 deaths globally. SARS-CoV-2 belongs to the β-coronavirus genus of the Coronavirus family, and it shares the same subfamily with severe acute respiratory syndrome-associated coronavirus (SARS-CoV) and Middle East respiratory syndrome-associated coronavirus (MERS-CoV), all of which lead to severe pneumonia. For cancer patients, especially those with lung cancers, their immune systems are compromised due to the disease itself as well as the treatment for cancer. The weakened immunity of these patients puts them at a higher risk of not only developing diseases but severe diseases. In this study, through a literature review and data collection, we focus on the selection and consideration of antitumor treatment strategies for advanced lung cancer during the coronavirus disease 2019 (COVID-19) epidemic.
has issue date	2020-08-03(xsd:dateTime)
bibo:doi	10.1007/s12032-020-01401-w
bibo:pmid	32748212
has license	no-cc
sha1sum (hex)	015f96637c2f224a7061e826128d72197cdbe757
schema:url	https://doi.org/10.1007/s12032-020-01401-w
resource representing a document's title	Considerations in treating patients with advance lung cancer during the epidemic outbreak of novel coronavirus (SARS-CoV-2)
has PubMed Central identifier	PMC7396726
has PubMed identifier	32748212
schema:publication	Med Oncol
resource representing a document's body	covid:015f96637c2f224a7061e826128d72197cdbe757#body_text
is schema:about of	named entity 'ITS' named entity 'PNEUMONIA' named entity 'SEVERE' named entity 'MERS-CoV' named entity 'coronavirus' named entity 'lead' named entity 'selection' named entity 'The' named entity 'respiratory' named entity 'tumor cells' named entity 'epidemic' named entity 'white blood cells' named entity 'World Health Organization' named entity 'EGFR' named entity 'diseases' named entity 'outbreak' named entity 'severe diseases' named entity 'severe pneumonia' named entity 'April 2020' named entity 'coronavirus' named entity 'MERS-CoV' named entity 'severe acute respiratory syndrome' named entity 'epidemic' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'immune systems are compromised' named entity 'global health emergency' named entity 'cytotoxicity' named entity 'immune function' named entity 'acute respiratory distress syndrome' named entity 'ROS1' named entity 'SARS-CoV-2' named entity 'angiogenesis' named entity 'lung cancer' named entity 'erlotinib' named entity 'severe pneumonia' named entity 'chemotherapeutic drugs' named entity 'viruses' named entity 'respiratory viral infections' named entity 'lung cancer' named entity 'COVID-19' named entity 'CD8 +' named entity 'trans-Golgi network' named entity 'Middle East' named entity 'GAK' named entity '1, 2' named entity 'external environment' named entity 'MERS' named entity 'incidence rates' named entity 'antiviral treatment' named entity 'immunotherapy' named entity 'fever' named entity 'EGFR' named entity 'COVID-19' named entity 'Epidermal growth factor receptor' named entity 'tumor growth' named entity 'immunotherapy' named entity 'GAK' named entity 'viral infection' named entity 'long-term' named entity 'small molecule' named entity 'EGFR' named entity 'EGFR' named entity 'immune cell' named entity 'lung cancer' named entity 'MERS-CoV' named entity 'immune function' named entity 'protein kinase' named entity 'lung cancer' named entity 'IFN-γ' named entity 'mortality rate' named entity 'viruses' named entity 'COVID-19'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software